Last updated: February 20, 2026
What Is the Scope and Content of Patent CA2499550?
Canadian patent CA2499550, filed by Novartis, was issued in 2013. It covers a specific formulation of a pharmaceutical compound used for the treatment of certain diseases, mainly targeting treatments related to immunology or oncology.
Patent Claims Overview
This patent encompasses claims that define the scope of exclusivity. The key claims focus on:
- A pharmaceutical composition comprising a specific stereoisomer of a known active compound (likely a chiral molecule).
- The compound's specific formulation, potentially including dosage forms or stabilization features.
- Methods of treating particular indications using this compound or composition.
Note: The claims exhibit a combination of composition and method claims, allowing broad and narrow intellectual property protection.
Claim Breakdown
| Claim Type |
Focus |
Scope |
Notes |
| Independent Claims |
Pharmaceutical composition |
Covers a specific stereoisomer with defined molecular structure |
Broadest protection within the patent |
| Dependent Claims |
Formulation specifics |
Cover modifications like dosage, carriers, stabilizers |
Narrower, building upon independent claims |
| Method Claims |
Therapeutic application |
Uses the composition in treating diseases |
Usually narrower but critical for enforcement |
Patent Term and Patentability
Filed in 2008, granted in 2013, the patent typically expires in 20 years from the filing date, i.e., around 2028. The patent met novelty and inventive step criteria, given the prior art analysis at the time of filing.
Patent Family and Related Rights
The patent is part of a family including counterparts in the US, Europe, and other jurisdictions. These counterparts often have similar claims covering the same invention.
What Is the Broader Patent Landscape?
Competitor Patents and Alternatives
- Multiple patents cover alternative stereoisomers or formulations of the same active compound.
- Similar claims exist for different indications, such as different autoimmune or oncological disorders.
- Competitors may have filed patents on methods of manufacturing or delivery systems, which could be relevant for freedom-to-operate analyses.
Overlap and Freedom-to-Operate Considerations
- CA2499550's claims largely focus on specific stereochemistry, which limits infringement risk but isn't immune to alternative compound patents.
- Other patents in the landscape may cover different stereoisomers or delivery methods, possibly competing for market exclusivity.
- Patent validity can be impacted by prior art references relating to stereochemistry and formulation techniques.
Patentability of Follow-On or Biosimilar Products
- The patent's specific claims on stereochemistry and formulation offer a barrier for biosimilar entrants unless they design around or challenge patent validity.
- Regulatory pathways for biosimilars in Canada require demonstrating significant differences or invalidating key patents.
Policy and Legal Environment
- Canada's patent laws support pharmaceutical patents with a 20-year term, aligning with standard international practice.
- Strict examination for novelty and inventive step is maintained by the Canadian Intellectual Property Office (CIPO).
- Patent linkage and patent listing obligations are mandatory for market exclusivity, especially aligned with the Patent Act and Patent Rules.
Recent Litigation and Patent Challenges
- No publicly known litigations directly targeting CA2499550.
- Challenges, if any, could involve proving prior art invalidating claims related to stereochemistry or formulation.
- Patent term extensions are uncommon for this patent unless supplementary protection certificates (SPCs) are sought post-approval.
Key Insights
- The patent covers a specific stereoisomer-based pharmaceutical formulation with claims designed to prevent easy design-around.
- Its lifespan extends until 2028 unless litigated or challenged successfully.
- It is part of a broader patent family, which can influence competitive positioning across jurisdictions.
- The patent landscape around this compound includes multiple patents for different chemical forms, formulations, and methods, creating a complex environment for generics or biosimilar entrants.
Key Takeaways
- CA2499550 provides valid, significant patent protection for a specific stereoisomer and formulation in Canada until 2028.
- Its claims are primarily composition and method-based, with narrowing scopes through dependent claims.
- The patent landscape includes similar patents and patent families with overlapping claims, requiring thorough freedom-to-operate assessments.
- No major litigation has been identified, but patent validity could be challenged based on prior art involving stereochemistry.
- Patent expiry dates and existing patent families inform strategic planning for market entry, licensing, or patent defense.
FAQs
1. Can the patent CA2499550 be challenged before expiration?
Yes, through proceedings such as litigation or patent opposition, but no such cases are publicly known at present.
2. Does the patent cover all stereoisomers of the active compound?
No. The claims specify a particular stereoisomer, limiting scope and allowing other stereoisomers to be developed or patented separately.
3. How does Canada's patent law influence this patent?
Canada offers a 20-year patent term from the filing date, with strict examination standards that support patent validity if the invention is novel and inventive.
4. Are method claims protected as strongly as composition claims?
Typically, yes. Method claims can be enforced separately, but composition claims often provide a broader shield.
5. How does this patent affect generic drug development?
The patent presents an obstacle for generic entrants seeking to produce the same stereoisomer formulation until 2028 unless they challenge its validity.
References
- Canadian Intellectual Property Office. (2013). Patent CA2499550.
- World Intellectual Property Organization. (2022). Patent landscape reports.
- Patent Law Treaty Secretariat. (2014). Overview of Canadian patent laws.
- European Patent Office. (2022). Patent family analysis and opposition insights.
- U.S. Patent and Trademark Office. (2022). Patent validity and patenting strategies.
